Department of Civil and Environmental Engineering, Northwestern University, Evanston, Illinois, USA.
Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
mSphere. 2021 Jun 30;6(3):e0006821. doi: 10.1128/mSphere.00068-21. Epub 2021 May 26.
Chemotherapeutic drugs can cause harmful gastrointestinal side effects, which may be modulated by naturally occurring members of our microbiome. We constructed simplified gut-associated microbial communities to test the hypothesis that bacteria-mediated detoxification of doxorubicin (i.e., a widely used chemotherapeutic) confers protective effects on the human microbiota. Mock communities composed of up to five specific members predicted by genomic analysis to be sensitive to the drug or resistant via biotransformation and/or efflux were grown over three generational stages to characterize community assembly, response to perturbation (doxorubicin exposure), and resilience. Bacterial growth and drug concentrations were monitored with spectrophotometric assays, and strain relative abundances were evaluated with 16S rRNA gene sequencing. Bacteria with predicted resistance involving biotransformation significantly lowered concentrations of doxorubicin in culture media, permitting growth of drug-sensitive strains in monoculture. Such protective effects were not produced by strains with drug resistance conferred solely by efflux. In the mixed communities, resilience of drug-sensitive members depended on the presence and efficiency of transformers, as well as drug exposure concentration. Fitness of bacteria that were resistant to doxorubicin via efflux, though not transformation, also improved when the transformers were present. Our simplified community uncovered ecological relationships among a dynamic consortium and highlighted drug detoxification by a keystone species. This work may be extended to advance probiotic development that may provide gut-specific protection to patients undergoing cancer treatment. While chemotherapy is an essential intervention for treating many forms of cancer, gastrointestinal side effects may precede infections and risks for additional health complications. We developed an model to characterize key changes in bacterial community dynamics under chemotherapeutic stress and the role of bacterial interactions in drug detoxification to promote microbiota resilience. Our findings have implications for developing bio-based strategies to promote gut health during cancer treatment.
化疗药物会引起有害的胃肠道副作用,而这些副作用可能可以通过我们微生物组中天然存在的成员进行调节。我们构建了简化的肠道相关微生物群落,以检验以下假设:即细菌介导的阿霉素(一种广泛使用的化疗药物)解毒作用对人类微生物组具有保护作用。模拟群落由基因组分析预测的多达 5 种特定成员组成,这些成员对药物敏感,或者通过生物转化和/或外排作用产生耐药性。这些模拟群落经过三个世代的生长来进行群落组装、对扰动(阿霉素暴露)的反应以及恢复能力的特征分析。通过分光光度测定法监测细菌生长和药物浓度,并通过 16S rRNA 基因测序评估菌株相对丰度。具有涉及生物转化的预测耐药性的细菌会显著降低培养基中阿霉素的浓度,从而使药物敏感菌株能够在纯培养中生长。通过外排作用产生的耐药性而不是单纯的药物耐药性的菌株不会产生这种保护作用。在混合群落中,药物敏感成员的恢复能力取决于转化器的存在和效率,以及药物暴露浓度。通过外排作用而不是生物转化对阿霉素具有耐药性的细菌的适应性也会随着转化器的存在而提高。我们的简化群落揭示了动态联合体之间的生态关系,并强调了关键物种的药物解毒作用。这项工作可以扩展到推进益生菌的开发,为接受癌症治疗的患者提供肠道特异性保护。虽然化疗是治疗多种癌症的重要干预手段,但胃肠道副作用可能先于感染和发生其他健康并发症的风险。我们开发了一种模型,以描述化疗应激下细菌群落动态的关键变化,以及细菌相互作用在药物解毒中的作用,以促进微生物组的恢复能力。我们的研究结果对开发基于生物的策略以促进癌症治疗期间的肠道健康具有重要意义。